Jessica Zamudio Bright, | |
1800 Edinburgh Street, Rawlins, WY 82301 | |
(307) 324-8820 | |
Not Available |
Full Name | Jessica Zamudio Bright |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 1800 Edinburgh Street, Rawlins, Wyoming |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003238718 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jessica Zamudio Bright, 3876 W 8920 S, West Jordan, UT 84088-9780 Ph: () - | Jessica Zamudio Bright, 1800 Edinburgh Street, Rawlins, WY 82301 Ph: (307) 324-8820 |
News Archive
Precise Biometrics AB has successfully completed a rights issue with preferential rights, which has supplied the Company with SEK 54.0 million prior to issue costs. The rights issue was subscribed to 178% and is implemented to finance further expansion and increase market penetration in prioritized segments.
A potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics is being reported in ACS' Journal of Medicinal Chemistry. It involves so-called FimH antagonists, which are non-antibiotic compounds and would not contribute to the growing problem of antibiotic resistance bacteria.
The strategies used to assess the environmental risks posed by pharmaceuticals are not enough to protect natural microbial communities, reveals a researcher from the University of Gothenburg (Sweden) who is calling for better environmental risk assessments.
A new clinical trial suggests that immunotherapy given before other treatments for oral cavity cancers can elicit an immune response that shrinks tumors, which could provide long-term benefit for patients.
Bio-Reference Laboratories, Inc. announced today that it has completed an equity investment in InCellDx, Inc., a privately held molecular diagnostics start-up company dedicated to the detection and monitoring of life -threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis and organ transplant rejection.
› Verified 5 days ago